Scholars Central

Conference abstractPublished 21 Nov 2016

Cancer immunotherapy

Authors: Sanjay R Jain

Morehouse School of Medicine, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The role of immune system in protection of the host against spontaneously arising tumors has been recognized for several centuries. The Natural Killer Cells perform an important function of immune surveillance against such tumors. However, our understanding of the mechanisms involved and more importantly of the mechanisms by which tumors escape and evade an immune response is limited. We are now beginning to better understand some of the pathways responsible for tumor destruction by immune cells. Therapeutic advances in the treatment of malignant melanoma and renal cancer and now lung cancer have allowed us an opportunity to harness the immune system against tumors and limit the use of cytotoxic chemotherapy with its attendant side effects. We still do not fully understand the epitopes on tumor cells towards which NK cells and other components of the immune system are directed; doing so will enable us to develop more effective immune therapies which have a sustained and effective response against tumors. Enrichment of Tumor Infiltrating Lymphocytes, the use of chimeric antigen receptors, anti CTLA-4, PD-1 and PDL1 directed therapies are a beginning in that effort and the combination of cellular and humoral approaches against tumors would likely allow for effective and relatively non-toxic and safer mechanisms of achieving durable and possibly life-long tumor control. Such approaches could also be utilized in primary prevention of sporadic and familial tumors. The history and current landscape of immune therapies is discussed. Also discussed are the toxicities and adverse effects associated with the use of immune therapies and possible future approaches of combinations of different components of the innate and adaptive immune systems, as well other classes of agents (chemotherapy, biological agents and radiation therapy). Possible experimental and clinical trial models are proposed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Sanjay R Jain”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels